Everything below concerns Lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
They achieve this by importing the lymphocytes from blood and lymph. According to the composition and activation status of the cells within the lymphoid structures, at least three organizational levels of TLOs have been described. The formation of TLOs starts with the aggregating of lymphoid cells and occasional DCs, but FDCs are lacking at this stage. The next stage is immature TLOs, also known as primary follicle-like TLS, which have an increased number of T cells and B cells with distinct T cell and B cell zones and the formation of FDCs network, but without germinal centres. Finally, fully mature (also known as secondary follicle-like) TLOs often have active germinal centres and high endothelial venules (HEVs), demonstrating a functional capacity by promoting T cell and B cell activation and then leading to expansion of TLS through cell proliferation and recruitment. During TLS formation, T and B cells are separated into two distinct but adjacent zones, with some cells able to migrate from one to the other, which is a crucial step in developing an effective and coordinated immune response. TLOs may play a key role in the immune response to cancer and serve as a prognostic marker for immunotherapy. TLOs have been reported to present in different cancer types such as melanoma, non-small-cell lung cancer and colorectal cancer (reviewed by Sautès-Fridman and colleagues in 2019), as well as glioma. TLOs are also seen as a read-out of treatment efficacy.
== Further reading == Oliver, Brian; Devitt, Catherine; Park, Grace; Razak, Alina; Liu, Sun Mei; Bergese, Sergio D. (2025). "Drugs in Development to Manage Acute Pain". Drugs. 85 (1): 11–19. doi:10.1007/s40265-024-02118-0. PMID 39560856. Broadfoot, Marla (20 August 2024). "New Painkiller Could Bring Relief to Millions—Without Addiction Risk". Scientific American. Archived from the original on 30 December 2024. Retrieved 20 July 2026.
By the summer of 1969 it was decided that a full band would be formed and David Nelson was recruited to play lead guitar. In addition to Nelson, Dawson (on acoustic guitar), and Garcia (continuing to play pedal steel), the original line-up of the band that came to be known as the New Riders of the Purple Sage (a nod to the Foy Willing-led Western swing combo from the 1940s, Riders of the Purple Sage, which borrowed its name from the Zane Grey novel) consisted of Alembic Studio engineer Bob Matthews on electric bass and Mickey Hart of the Grateful Dead on drums; bassist Phil Lesh also played sporadically with the ensemble in lieu of Matthews through the end of the year, as documented by the late 1969 demos later included on the Before Time Began archival release. Lyricist Robert Hunter briefly rehearsed with the band on bass in early 1970 before the permanent hiring of Torbert in April of that year. The most commercially successful configuration of the New Riders would come to encompass Dawson, Nelson, Torbert, Spencer Dryden, and Buddy Cage.
==== Musculoskeletal pain ==== The benefits of paracetamol in musculoskeletal conditions, such as osteoarthritis and backaches, are uncertain. It appears to provide only small and not clinically important benefits in osteoarthritis. The guidelines of the American College of Rheumatology and Arthritis Foundation for the management of osteoarthritis note that the effect size in clinical trials of paracetamol has been very small, suggesting that for most individuals it is ineffective. The guideline conditionally recommends short-term and episodic use of paracetamol to those who do not tolerate nonsteroidal anti-inflammatory drugs. For people taking it regularly, monitoring for liver toxicity is required. The same recommendation was issued by the European League Against Rheumatism for hand osteoarthritis. Similarly, the ESCEO algorithm for the treatment of knee osteoarthritis recommends limiting the use of paracetamol to short-term rescue analgesia only. Paracetamol is ineffective for acute low back pain. No randomized clinical trials evaluated its use for chronic or radicular back pain, and the evidence in favor of paracetamol is lacking.
Sources: en.wikipedia.org
The purpose of using the vacuum is to eliminate background signal and avoid intermolecular collision events, therefore, providing a long mean free path for the ions. The vacuum system, including the vacuum pumps and the vacuum manifold with its various interfaces, is often the heaviest part and consumes the most power in a mass spectrometer. In the case of TOF, if the length of drift region is decreased, the pressure inside region can be operated at higher value because the free collision region is still maintained for a short traveling distance of the ions. As a result, the vacuum system requires less power to run the system. For a trap-type mass analyzer, because the ions are trapped in the device for long periods and the accumulated trajectory length is much longer than the size of the mass analyzer, the size reduction of the mass analyzer may not directly affect the adequate operating pressure. Miniature rough-turbo pump configurations similar to lab-scale instruments have been developed to be compatible with MMS. For high-vacuum pumping, turbomolecular pumps are also upgraded. A Thermo Fisher Orbitrap used three turbo pumps in LC-MS modes to achieve a vacuum below 10−10 torr. Recently, a turbo pump from Creare, Inc.TM weighs only 500g and needs below 18 W power to run. The pump can provide the ultimate vacuum below 10−8 torr, which is much lower than the operating pressure necessary for a MMS.
The adsorption/desorption processes of a permeant's molecule normally exhibit a linear dependency with the partial pressure gradient across the barrier layer, while keeping the assumption of steady-state transport conditions and exhibiting a concentration lower than the penetrant's maximum solubility, thereby adhering to Henry's law of solubility. The type of permeant, the barrier layer's thickness, the specific permeabilities of the packaging films against gases or vapors, the packaging's permeable area, the temperature, and the pressure or concentration gradient between the barrier's interior and external sides can all have an impact on a system's permeability. The gas exchange occurring between the packaging system and the external environment has a significant impact on the quality and safety of food products. Uncontrolled physico-chemical and biological processes, such as oxidation of vitamins, excessive microbial growth, and spoilage of the packed food, may lead to improper conditions inside the packaging headspace, hence reducing their shelf-life. Therefore, the packaging system should be designed to create the ideal conditions for the selected product, avoiding excessive gas exchange. Among the permeants that could affect the organoleptic properties of food, oxygen and water vapor represent the most important ones.
The most common and widely known tempeh is made from fermented soybeans, called tempeh kedele or tempeh dele, made from controlled fermentation of soybeans. However, traditionally other ingredients such as ampas tahu (tofu dregs/okara), ampas kelapa (coconut dregs) and peanuts may be used in a fashion similar to the tempeh-making process, although perhaps using different fungi or attracting other microbes like kara benguk or kara pedhang, which can be toxic if not prepared correctly. A related product to tempeh is oncom, which is made from peanut press cake or soy dregs and is prevalent in Sundanese culture in West Java. There are two types of oncom: a bright red-orange kind with Neurospora sitophila, and a black one with the same fungi as tempeh uses.
Even after the Meiji era when hybrid cattle were encouraged, there were still a considerable number of pure Wagyu cattle remaining in the Taisho era (1912–1926). As a policy for the improvement of Wagyu, efforts were made to eliminate negative characteristics of hybrid cattle as much as possible. Specifically, the elimination of sudare (tiger stripes), nori-kuchi (grayish-white lips), unagi-sen (different fur color on the dorsal line), white spots, etc. On the other hand, efforts were made to improve the physique and weight of both pure and improved Wagyu cattle, and from around the 1920s, the term "improved Wagyu" came to refer to all Wagyu cattle, including not only improved Wagyu but also pure Wagyu. Around 1919, the examination and registration of Wagyu began mainly in western Japan, and pedigrees and body types began to be registered. Nine breeds were registered: Tajima, Bisaku, Hiroshima, Bocho, Shimane, Inhaku, Bungo, Kumamoto, and Kagoshima. However, the examination and registration process was carried out by each prefecture, and the criteria for examination varied. Around 1925, the results of the improvements became visible: the negative characteristics of crossbreeding had almost disappeared from Wagyu cattle, their size and weight had increased, and improvements in hindquarters were clearly visible.
After death, a body will decay. Burial is not necessarily a public health requirement. Contrary to conventional wisdom, the World Health Organization advises that only corpses carrying an infectious disease strictly require burial. Human burial practices are the manifestation of the human desire to demonstrate "respect for the dead". Cultures vary in their mode of respect. Some reasons follow:
Sources: en.wikipedia.org
This may also be considered in patients for whom lifestyle therapy has failed, or is not sustainable, who are at high-risk for developing type 2 diabetes, or who prefer to take a medication. Metformin and acarbose help prevent the development of prediabetes, and also have a good safety profile. Evidence also supports thiazolidinediones but there are safety concerns, and data on newer agents such as GLP-1 receptor agonists, DPP4 inhibitors or meglitinides are lacking.
== Function and Terminology == The “pre-” prefix of preproglucagon indicates that it is composed of proglucagon together with a signal peptide. The signal peptide is a 20 amino acid fragment that signals that the protein needs to be secreted out of the cell. Proglucagon has the “pro-“ prefix because it is a prohormone, which means it is an inactivate precursor that needs to be further modified in order to produce active hormone(s). In particular, proglucagon is cleaved (cut) into different active hormones depending on the organ. Omitting various inactive fragments, preproglucagon is cleaved into the following:
In America, in the late 1990s/early 2000s a new type of tablet counter appeared. It was simple to use, compact, inexpensive, and had good counting accuracy. At the turn of the millennium technical advances allowed the design of counters with a software verification system. With an onboard computer, displaying photo images of medications to assist the pharmacist or pharmacy technician to verify that the correct medication was being dispensed. In addition, a database for storing all prescriptions that were counted on the device. Between September 2005 and May 2007, American Capital made a major financial investment in Kirby Lester, which then relocated to a larger facility to expand its research and development capabilities. This move added extra space for product research and development facility (R&D). It allowed the opportunity to develop new advanced technology products that met the pharmacy's needs for simple, accurate, and cost-effective ways to dispense prescriptions safely. Pictured here is an early American type of integrated counter and packaging device. This machine was a third generation step in the evolution of pharmacy automated devices. Later models held pre-counted containers of commonly-prescribed medications.
Calcitonin can be used therapeutically for the treatment of hypercalcemia or osteoporosis. In a recent clinical study, subcutaneous injections of calcitonin have reduced the incidence of fractures and reduced the decrease in bone mass in women with type 2 diabetes complicated with osteoporosis. Subcutaneous injections of calcitonin in patients with mania resulted in significant decreases in irritability, euphoria and hyperactivity and hence calcitonin holds promise for treating bipolar disorder. However no further work on this potential application of calcitonin has been reported.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.